Patents Assigned to Genentech
  • PROTEIN PURIFICATION
    Publication number: 20190352333
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.
    Type: Application
    Filed: August 6, 2019
    Publication date: November 21, 2019
    Applicant: Genentech, Inc.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona O'Leary
  • Immediate-release tablets containing combimetinib and methods of making and using the same
    Patent number: 10478400
    Abstract: The present disclosure relates generally to rapid-release pharmaceutical dosage unit tablets containing a drug that is an inhibitor of the mitogen-activated protein kinase enzyme, a filler and a disintegrant, and to processes for forming the tablets. More specifically, the present disclosure relates to pharmaceutical dosage unit tablets containing cobimetinib, a least one filler, at least one lubricant and at least one disintegrant, and to methods for preparing the tablets from granules formed by dry granulation.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: November 19, 2019
    Assignee: Genentech, Inc.
    Inventors: Sanjeev Kothari, Priscilla Mantik, Alexander Mauerer, Hamid Rezaei
  • PYRAZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20190345165
    Abstract: Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: June 25, 2019
    Publication date: November 14, 2019
    Applicant: Genentech, Inc.
    Inventors: F. Anthony ROMERO, Mark ZAK, Guiling ZHAO, Paul GIBBONS, Wei LI, Yun-Xing CHENG, Po-Wai YUEN, Limin CHENG
  • PERTUZUMAB VARIANTS AND EVALUATION THEREOF
    Publication number: 20190345258
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab.
    Type: Application
    Filed: July 12, 2019
    Publication date: November 14, 2019
    Applicant: Genentech, Inc.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • IDIOTYPIC ANTIBODIES AGAINST ANTI-PD-L1 ANTIBODIES AND USES THEREOF
    Publication number: 20190338034
    Abstract: The invention provides anti-idiotypic antibodies against anti-PD-L1 antibodies and methods of using the same.
    Type: Application
    Filed: July 15, 2019
    Publication date: November 7, 2019
    Applicant: Genentech, Inc.
    Inventors: Jo-Anne Hongo, Angie Yee, Christine Tan, Joyce Lai, Joanne Adamkewicz, John Byon
  • TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20190337946
    Abstract: Triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.
    Type: Application
    Filed: July 18, 2019
    Publication date: November 7, 2019
    Applicant: Genentech, Inc.
    Inventors: Simon Charles Goodacre, Nicholas Charles Ray, Mark Edward Zak, Yun-Xing Cheng, Wei Li
  • CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
    Publication number: 20190337965
    Abstract: The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: July 16, 2019
    Publication date: November 7, 2019
    Applicant: Genentech, Inc.
    Inventors: Jeffrey A. STAFFORD, James M. VEAL, Lynnie Lin TRZOSS, Christopher MCBRIDE
  • Diagnostic methods and compositions for treatment of glioblastoma
    Patent number: 10456470
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: October 29, 2019
    Assignee: Genentech, Inc.
    Inventors: Carlos Bais, Richard Bourgon, Heidi Phillips, Thomas Sandmann
  • Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
    Patent number: 10457648
    Abstract: The present disclosure relates to processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds, and more particularly relates to processes for preparing (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d] pyrimidin-4-yl)piperazine and N-protected derivatives thereof, which may be used as an intermediate in the synthesis of Ipatasertib (i.e., (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)-propan-1-one). The present disclosure additionally relates to various compounds that are intermediates employed in these processes.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: October 29, 2019
    Assignees: GENENTECH INC., F. HOFFMANN-LA ROCHE AG
    Inventors: Francis Gosselin, Chong Han, Hans Iding, Reinhard Reents, Scott Savage, Beat Wirz
  • Compounds and compositions for the inhibition of NAMPT
    Patent number: 10456382
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: October 29, 2019
    Assignees: FORMA TM, LLC, Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
  • Therapeutic compounds and methods of use thereof
    Patent number: 10457654
    Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1—Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: October 29, 2019
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Daniel Sutherlin, Steven McKerrall, Michael Scott Wilson, Kwong Wah Lai, Philippe Bergeron, Birong Zhang, Ramsay Beveridge, Jean-Philippe Leclerc, Alexandre Lemire, Liang Zhao, Claudio Sturino
  • GENE EXPRESSION MARKERS OF TUMOR RESISTANCE TO HER2 INHIBITOR TREATMENT
    Publication number: 20190323089
    Abstract: The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab.
    Type: Application
    Filed: July 2, 2019
    Publication date: October 24, 2019
    Applicant: Genentech, Inc.
    Inventors: Si Tuen Lee-Hoeflich, Howard Stern
  • 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20190322661
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: June 11, 2019
    Publication date: October 24, 2019
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-wai Yuen
  • COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOF
    Publication number: 20190322761
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Application
    Filed: July 3, 2019
    Publication date: October 24, 2019
    Applicant: Genentech, Inc.
    Inventors: Reed J Harris, Paul A. Motchnick
  • STABLE ANTI-CD79B IMMUNOCONJUGATE FORMULATIONS
    Publication number: 20190314517
    Abstract: The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.
    Type: Application
    Filed: April 12, 2019
    Publication date: October 17, 2019
    Applicant: Genentech, Inc.
    Inventors: Ankit R. PATEL, Jun LIU
  • 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
    Patent number: 10442836
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: October 15, 2019
    Assignee: Genentech, Inc.
    Inventors: John Flygare, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, William Denny, Anna Giddens, Ho Lee, Guo-Liang Lu, Christian Miller, Gordon Rewcastle, Moana Tercel, Muriel Bonnet
  • ELUCIDATION OF ION EXCHANGE CHROMATOGRAPHY INPUT OPTIMIZATION
    Publication number: 20190310234
    Abstract: The present invention provides methods for determining chromatography separation conditions; for example, separation of a polypeptide and its charge variants. The invention also provides methods to determine a buffer condition for chromatography separation conditions. The invention also provides a robust method to analyze multiple polypeptide products.
    Type: Application
    Filed: March 12, 2019
    Publication date: October 10, 2019
    Applicant: Genentech, Inc.
    Inventors: Daniel McDonald, Thomas Patapoff, Yajun Wang
  • USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS
    Publication number: 20190310266
    Abstract: The present invention is directed to methods of using biomarkers to assess treatment of gastrointestinal inflammatory disorders with beta7 antagonists. More particularly, the present invention relates to methods of using the level of gut-homing lymphocytes in peripheral blood, the level of drug occupancy on gut-homing lymphocytes, and/or the level of beta7 integrin receptors on gut-homing lymphocytes as indicators (or biomarkers) of the effect, efficacy, safety, prognosis, and/or dosing of therapeutic agents, such as beta7 integrin antagonists, for the treatment of gastrointestinal inflammatory disorders.
    Type: Application
    Filed: November 20, 2018
    Publication date: October 10, 2019
    Applicant: GENENTECH, INC.
    Inventors: Thomas Richard Gelzleichter, Hajime Hiraragi, Eric Gary Stefanich, Hong Wang, Marna Bromberg Williams
  • Processes for the preparation of pyrimidinylcyclopentane compounds
    Patent number: 10435378
    Abstract: The present invention relates to a process for the preparation of a compound of formula (I) wherein R1 is as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: October 8, 2019
    Assignee: GENENTECH, INC.
    Inventors: Hans Iding, Reinhard Reents, Michelangelo Scalone, Francis Gosselin
  • Methods and compositions for secretion of heterologous polypeptides
    Patent number: 10435694
    Abstract: The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: October 8, 2019
    Assignee: Genentech, Inc.
    Inventors: Dorothea Reilly, Yizhou Zhou